Key result
CRT reduces all-cause mortality ~40% and decreases hospitalizations in advanced heart failure with dyssynchrony.
Why the study?
With the increasing use of CRT in severe and chronic HF, clinicians need to understand its emerging role, evidence, benefits, and indications.
Answers are grounded in this paper and cite their sources.
Supports guideline-directed CRT in NYHA III-IV HF; confirms prior evidence while leaving open refinements in selection.
Implication for health policy/practice/research/medical education:This review is intended for those managing patients of heart failure and aims to provide the recent advances and emerging role of CRT implantation in heart failure management.Cardiac resynchronization therapy (CRT) represents one of the recent advances in heart failure (HF) management.It implies an attempt to establish left ventricular synchronous contraction in order to improve left ventricular hemodynamics; thereby improving functional class, and quality of life.CRT has come a long way from an incidental treatment modality to an accepted and indicated treatment strategy for patients suffering from severe and chronic heart failure.With its ever increasing use, it is important that we become conversant with its role in the management of heart failure.This article aims to review the evidence for CRT, how CRT benefits patients of heart failure and reveals the indications of CRT implantation in HF patients.
No takes yet. Share an insight, caveat, or question.
Wahab et al. (2011) conducted a review in Heart Failure. Cardiac resynchronization therapy (CRT) vs. Optimized medical therapy alone was evaluated. Cardiac resynchronization therapy reduces all-cause mortality by 36% to 43% and decreases hospitalizations in patients with NYHA Class III-IV heart failure and ventricular dyssynchrony.
Synapse has enriched 10 related papers. Consider them for comparative context: